MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission
13 Setembro 2022 - 1:15PM
Business Wire
The licence agreement complements the collaboration between
Medincell and the health agency Unitaid that funds the development
of mdc-STM, an investigational long-acting injectable formulation
for the prevention of malaria.
The Medicines Patent Pool (MPP) is a United Nations-backed
public health organisation working to increase access to, and
facilitate the development of life-saving medicines for low- and
middle-income countries.
The licence agreement relates to a 3-Month active injectable
formulation of ivermectin using Medincell’s BEPO® technology to
fight malaria transmission.
The licence agreement aims to ensure that the product be
widely distributed in low- and middle-income countries if proven
effective and safe.
Malaria remains endemic in 91 countries leading to 627,000
deaths in 2020. Children under 5 are the most vulnerable,
accounting for 80% of deaths.
Click here to access the full press release
About MedinCell
MedinCell is a pharmaceutical company at premarketing stage that
develops a portfolio of long-acting injectable products in various
therapeutic areas by combining its proprietary BEPO® technology
with active ingredients already known and marketed. Through the
controlled and extended release of the active pharmaceutical
ingredient, MedinCell makes medical treatments more efficient,
particularly thanks to improved compliance, i.e. compliance with
medical prescriptions, and to a significant reduction in the
quantity of medication required as part of a one-off or chronic
treatment. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months starting from the
subcutaneous or local injection of a simple deposit of a few
millimeters, fully bioresorbable. MedinCell collaborate with tier
one pharmaceuticals companies and foundations to improve Global
Health through new therapeutic options. Based in Montpellier,
MedinCell currently employs more than 150 people representing over
30 different nationalities.
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220913006088/en/
MPP: press@medicinespatentpool.org
MedinCell David Heuzé Communication leader
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier/Mathilde Bohin Investor Relations
medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024